France grants reimbursed compassionate access to Agenus’ BOT/BAL for refractory MSS metastatic CRC, offering new hope for patients.

BOT/BAL Advancements, BATTMAN Trial, FDA Approval Challenges and Key Highlights from Agenus Stakeholder Briefing / Agenus, BATTMAN trial, botensilimab,

Four Agenus Abstracts Have Been Accepted for Presentation at ESMO25 / Agenus, cancer, colorectal cancer, ESMO25, immunotherapy, OncoDaily, Oncology

Agenus' Investigator's Forum 2025: BOT/BAL Advancing Immunotherapy in Solid Tumors / Agenus, Agenus' Investigator's Forum, Balstilimab, BATTMAN trial,

Garo Armen Shares a Personal Story Driving Agenus' Mission in Cancer Care / Agenus, cancer, Garo Armen, Headlines, National Cancer Survivor Month, OncoDaily,

Agenus Enters New Era With $141M Zydus Deal Signaling Strategic Transformation in Immuno-Oncology / Agenus, biotech, botensilimab, cancer, cancer care, Cancer

Agenus and Zydus Group Announced a $141M Strategic Collaboration to Advance the Manufacturing and Global Development of BOT/BAL / Agenus, BOT/BAL, cancer,

Zynext Ventures has invested in Agenus Inc., boosting its immuno-oncology pipeline and supporting innovation in cancer therapies. This collaboration aims to accelerate treatment development for high-unmet need cancers.

Zydus Lifesciences is making a strategic move into the biologics CDMO sector, aiming to acquire Agenus' U.S. manufacturing facilities to enhance innovative therapy development.

Investing.com -- Agenus Inc . (NASDAQ:AGEN) stock soared 30% following the announcement of a strategic collaboration with Zydus Lifesciences, which includes a $141 million deal to advance BOT/BAL and expand Zydus’ biologics manufacturing in the United States. The partnership agreement, which involves exchanging Agenus’ biologics CMC facilities in California for an upfront consideration of $75 million and up to an additional $50 million in contingent payments, has been designed to accelerate the clinical development and scale global manufacturing. Zydus will also launch a BioCDMO business in the U.S. with Agenus as its first customer, ensuring the manufacturing readiness of BOT/BAL for BLA submission and potential commercial launch. Furthermore, Agenus will receive a 5% royalty on net sales from Zydus in India and Sri Lanka, where Zydus will have the exclusive license to develop and commercialize these therapies. Additionally, Zydus will make a strategic equity investment in Agenus by purchasing approximately 2.1 million shares at $7.50 per share, totaling around $16 million. The CEO of Agenus, Dr. Garo Armen, highlighted the trade agreement between the United States and India as a positive step towards strengthening Indian-American relations and ensuring secure biopharma supply chains. He expressed confidence in the partnership’s potential to accelerate future clinical trials and expand the global oncology therapeutics footprint of BOT/BAL. Dr. Sharvil Patel, Managing Director at Zydus Lifesciences, expressed enthusiasm for the partnership, noting the potential benefits for patients in India, Sri Lanka, and globally. Zydus plans to conduct clinical trials for BOT/BAL in various stages of disease and expand its use beyond colorectal cancer to other significant diseases such as triple-negative breast cancer. The transaction is subject to customary closing conditions and due diligence, with the parties expecting to complete closing agreements within 60 days. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Richard Goldberg: Agenus Anticipates Interacting with FDA with New Data Coming at ESMO-GI 2025 / Agenus, cancer, ESMO GI 2025, FDA, Headlines, OncoDaily,

Agenus Names Leading GI Oncologist Dr. Richard Goldberg as Chief Development Officer / cancer, colorectal cancer, Garo Armen, GI oncology, OncoDaily,

Agenus Bets Big on Botensilimab / 10 most promising drugs, Agenus, botensilimab, cancer, fda aproval, Headlines, OncoDaily, Oncology

Breelyn Wilky Discusses Promising Phase 1 Results of BOT/BAL in Advanced Sarcomas - Agenus / Agenus, Breelyn Wilky, cancer, OncoDaily, Oncology

Agenus partners with Fight Colorectal Cancer to drive awareness and action for CRC / Agenus, cancer, colorectal cancer, Colorectal Cancer Awareness Month,

Recognizing Colorectal Cancer Awareness Month - Agenus / Agenus, cancer, colorectal cancer, Colorectal Cancer Awareness Month, CRC, OncoDaily, Oncology

Learn how a novel combination of Botensilimab and Balstilimab demonstrates promising efficacy in traditionally immunotherapy-resistant sarcomas.

Botensilimab: A Novel Anti-CTLA- 4 Therapy Effectively Treats Refractory Colorectal Cancers / Agenus, botensilimab, cancer, colorectal cancer, Dhan Chand,

Agenus and Tanner Pharma Partner to Expand Global Access to BOT/BAL / Agenus, Balstilimab, botensilimab, cancer, OncoDaily, Oncology, Tanner Pharma Group

Gevorg Tamamyan: 80 speakers and around 450 participants from 30 countries / Agenus, cancer, colorectal cancer, Gevorg Tamamyan, OncoDaily, Oncology